Related Experiment Video
Updated: May 12, 2026
Culture of Bladder Cancer Organoids as Precision Medicine Tools
Published on: December 28, 2021
Clinical applications of recent molecular advances in urologic malignancies: no longer chasing a "mirage"?
1Department of Pathology, Johns Hopkins University, Baltimore, MD 21231, USA. gnetto1@jhmi.edu
Abstract:
As our understanding of the molecular events leading to the development and progression of genitourologic malignancies, new markers of detection, prognostication, and therapy prediction can be exploited in the management of these prevalent tumors. The current review discusses the recent advances in prostate, bladder, renal, and testicular neoplasms that are pertinent to the anatomic pathologist.
Insights
Recent advances in genitourinary cancer molecular understanding offer new detection and treatment markers. Anatomic pathologists can utilize these insights for improved prostate, bladder, renal, and testicular neoplasm management.
Area of Science:
- Oncology
- Molecular Pathology
- Genitourinary Neoplasms
Background:
- Genitourinary malignancies, including prostate, bladder, renal, and testicular cancers, are prevalent tumors with complex molecular underpinnings.
- Understanding the molecular events driving cancer development and progression is crucial for effective patient management.
Purpose of the Study:
- To review recent advancements in genitourinary neoplasms relevant to anatomic pathology.
- To highlight novel molecular markers for detection, prognostication, and therapy prediction.
Main Methods:
- Literature review of recent scientific publications.
- Focus on molecular insights and their clinical applicability.
Main Results:
- Identification of emerging molecular markers across prostate, bladder, renal, and testicular cancers.
- Discussion of how these markers impact diagnostic and therapeutic strategies.
Conclusions:
- Enhanced understanding of molecular events in genitourinary cancers facilitates the development of new diagnostic and prognostic tools.
- Anatomic pathologists play a key role in integrating these molecular advances into the clinical management of genitourinary neoplasms.
